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BACKGROUND AND PURPOSE
Ligand–receptor binding kinetics is receiving increasing attention in the drug research community. The Motulsky and Mahan
model, a one-state model, offers a method for measuring the binding kinetics of an unlabelled ligand, with the assumption that
the labelled ligand has no preference while binding to distinct states or conformations of a drug target. As such, the one-state
model is not applicable if the radioligand displays biphasic binding kinetics to the receptor.
EXPERIMENTAL APPROACH
We extended the Motulsky and Mahan model to a two-state model, in which the kinetics of the unlabelled competitor binding to
different receptor states (R1 and R2) can be measured. With this extended model, we determined the binding kinetics of
unlabelled N-50-ethylcarboxamidoadenosine (NECA), a representative agonist for the adenosine A1 receptor. Subsequently, an
application of themodel was exemplified bymeasuring the binding kinetics of other A1 receptor ligands. In addition, limitations of
the model were investigated as well.
KEY RESULTS
The kinetic rate constants of unlabelled NECA were comparable with the results of kinetic radioligand binding assays in which
[3H]-NECA was used. The model was further validated by good correlation between simulated results and the experimental data.
CONCLUSION
The two-state model is sufficient to analyse the binding kinetics of an unlabelled ligand, when a radioligand shows biphasic as-
sociation characteristics. We expect this two-state model to have general applicability for other targets as well.
Abbreviations
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate; CPA, N6-cyclopentyladenosine; DPCPX, 1,3-
dipropyl-8-cyclopentylxanthine; LUF5962, 8-cyclopentyl-2,6-diphenyl-9H-purine; NECA, N-50-ethylcarboxamidoadenosine
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Introduction
The kinetics of ligand–receptor binding constitute a topic of
increasing concern in the early phase of the drug design and
discovery process. The importance of this topic has recently
been emphasized in several reviews (Swinney, 2009;
Copeland, 2016; Guo et al., 2017). These discussions led to
an increased recognition of the importance of binding kinet-
ics in the preclinical stages of drug discovery. In particular, the
drug-target residence time (1·koff
1) represents an experimental
description of the stability of the ligand–receptor binary com-
plex, which is suggested as a better predictor than steady-
state metrics, such as affinity values, in terms of the duration
of a pharmacological effect and target selectivity (Copeland
et al., 2006; Guo et al., 2014; Swinney et al., 2015).
Experimental approaches for kinetic measurements are
available, and new technologies are emerging (Hoffmann
et al., 2015). Among current experimental strategies, kinetic
radioligand binding assays enable straightforward kinetic
profiling of a labelled ligand on a given receptor. However,
the process of labelling compromises its practicability in
large-scale determinations. Alternative strategies enabling
quantitative kinetic profiling of unlabelled ligands have been
developed (Motulsky and Mahan, 1984; Malany et al., 2009;
Packeu et al., 2010). One representative method is the so-called
competition association assay based on the mathematical
model developed by Motulsky and Mahan (1984). This model
can be described by the following pair of reaction equations:
Aþ R⇄AR
Bþ R⇄BR

: (1)
Briefly, an unlabelled ligand of interest (i.e. the competi-
tor, B) is co-incubated with a well-characterized radioligand
(A), both competitively binding to the receptor (R). The com-
petitor may delay the time-dependent increase of radioligand
binding or even produce a time-dependent decrease in
radioligand binding after an initial ‘overshoot’ (Packeu
et al., 2010). These procedures allow an accurate estimation
of a competitor’s dissociation rate, as demonstrated by several
analyses using GPCRs (Dowling and Charlton, 2006; Guo
et al., 2012, 2013; Vilums et al., 2013; Nederpelt et al., 2016)
as well as theKv11.1 ion channel (Yu et al., 2015). The model
is applied with the assumption that the labelled ligand has no
preference while binding to distinct receptor states or confor-
mations, hence representing a one-state model (R). However,
it is known that a radioligand may display biphasic binding
characteristics to the receptor. For instance, an agonist
radioligand often has a strong preference for a given state of
a GPCR over another, thus resulting in a biphasic association
(Munshi et al., 1985; van Veldhoven et al., 2015). In this situ-
ation, the one-state model is no longer applicable for quanti-
tative kinetic measurements.
In the present study, we have extended the Motulsky and
Mahanmodel into a two-state receptormodel (R1 and R2) that
enables kinetic profiling of an unlabelled competitor using a
radioligand that displays biphasic kinetic radioligand
binding. The human adenosine A1 receptor was used as a
prototypical target. For model validation, the binding
kinetics of an unlabelled adenosine receptor agonist, N-50-
ethylcarboxamidoadenosine (NECA), was measured and
analysed using the two-state receptor model and compared
with the kinetic parameters obtained with the tritiated probe
[3H]-NECA in a classical association and dissociation experi-
ment. Themodelwas further validated by comparing simulated
results with the experimental data. Furthermore, the kinetics of
another unlabelled agonist, N6-cyclopentyladenosine (CPA),
was measured and analysed to demonstrate the applicability
of this novel two-state model. Finally, the model was also used
to study the binding kinetics of two antagonists, 1,3-dipropyl-
8-cyclopentylxanthine (DPCPX) and 8-cyclopentyl-2,6-
diphenyl-9H-purine (LUF5962).
Methods
Group sizes
Numbers (n) for all experiments are provided and refer to in-
dependent single measurements.
Randomization
Randomization was not applicable, hence not performed.
Blinding
Blinding of experiments is not applicable.
Cell culture and membrane preparation
Cell culture andmembrane preparation were performed as re-
ported previously (Guo et al., 2013). CHO cells stably express-
ing the human adenosine A1 receptor (CHOhA1R cells)
were grown in Ham’s F12 medium containing 10% (v/v) nor-
mal adult bovine serum, streptomycin (100 μg·mL1), peni-
cillin (100 IU·mL1) and G418 (0.4 mg·mL1) at 37°C in 5%
CO2. Cells were subcultured twice weekly at a ratio of 1:20
on 10 cm diameter culture plates.
For membrane preparation, cells were subcultured 1:10
and then transferred to 15 cm plates. Cells grown to 80 to
90% confluency were detached from plates by scraping them
into 5 mL PBS, collected and centrifuged at 700 x g for 5 min.
Cell pellets derived from 30 plates were pooled and resus-
pended in 20 mL of ice-cold 50 mM Tris–HCl buffer
(pH 7.4). An UltraTurrax (Heidolph Instruments, Schwabach,
Germany) was used to homogenize the cell suspension.
Membranes and the cytosolic fraction were separated by cen-
trifugation at 100 000 x g in a Beckman Optima LE-80K ultra-
centrifuge (Beckman Coulter, Fullerton, CA) at 4°C for
20 min. The pellet was resuspended in 15 mL of the
Tris–HCl buffer, and the homogenization and centrifugation
step were repeated. Tris–HCl buffer (10 mL) was used to resus-
pend the pellet, and adenosine deaminase (0.8 IU·mL1)
was added to break down endogenous adenosine. Mem-
branes were stored in 250 μL aliquots at 80°C. Concentra-
tions of the membrane protein were measured using the
bicinchoninic acid assay method (Smith et al., 1985).
Competition binding assays
Membrane aliquots containing 40 μg of protein were incu-
bated in a total volume of 100 mL of assay buffer (50 mM
Tris–HCl, pH 7.4, supplemented with 5 mM MgCl2 and
0.1% w·v1 CHAPS) at 30°C for 3 h to ensure the equilibrium
was reached. Radioligand displacement experiments were
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performed using six concentrations of a competing ligand in
the presence of ~18 nM [3H]-NECA. Non-specific binding was
determined in the presence of 100 μMNECA and represented
less than 10% of the total radioligand binding. All concentra-
tions mentioned here and in following sections are final con-
centrations. Incubations were terminated by rapid vacuum
filtration to separate the bound and free radioligand through
Whatman GF/B filters (Whatman International, Maidstone,
UK) with a Brandel harvester or using a PerkinElmer
Filtermate harvester (Groningen, The Netherlands). Filters
were washed 3 times with ice-cold wash buffer (50 mM
Tris–HCl, 5 mM MgCl2, pH 7.4). The filter-bound radioactiv-
ity was determined by scintillation spectrometry using a liq-
uid scintillation counter (Tri-Carb 2900 TR, PerkinElmer) or
a Microbeta Wallac Trilux scintillation counter (P-E 1450,
Perkin Elmer).
Kinetic radioligand binding experiments
Association experiments were performed by incubating
membrane aliquots containing 40 μg of protein in a total vol-
ume of 100 μL of assay buffer with ~18 nM [3H]-NECA at
30°C. The amount of radioligand bound to the receptor was
measured at different time intervals during incubation for
3 h. Dissociation experiments were performed by preincubat-
ing CHOhA1R cell membranes in a total volume of 100 μL of
assay buffer with ~18 nM [3H]-NECA at 30°C for 2 h. Subse-
quently, the dissociation was initiated by addition of 10 μM
DPCPX in 5 μL. The amount of radioligand still bound to
the receptor was measured at different time intervals for a to-
tal duration of 7 h at 30°C to ensure that the radioligand was
fully dissociated from the receptor. Non-specific binding was
determined in the presence of 100 μMNECA and represented
less than 10% of the total radioligand binding. Incubations
were terminated, and samples were obtained as described un-
der Competition binding assays.
Two-state competition association assays
The binding kinetics of unlabelled ligand were determined at
30°C using the two-state model as mentioned below. The ex-
periment was initiated by adding membrane aliquots con-
taining 40 μg of protein at different time points to a total
volume of 100 μL assay buffer with ~18 nM [3H]-NECA in
the absence or presence of a competing ligand at three con-
centrations (approximately 0.3×, 1× and 3× IC50). Incuba-
tions were terminated, and samples were obtained as
described under Competition binding assays.
The two-state model
Here, we consider kinetics for a two-state receptor system (R1
and R2) and a radioligand (A) in the presence of an unlabelled
competitor (B). Both bind reversibly to the receptors with spe-
cific kinetic constants following the law of mass action. This
yields the following generalization of the model:
Aþ R1⇄
k1
k2
AR1
Aþ R2⇄
k3
k4
AR2
8><
>: and
Bþ R1⇄
k5
k6
BR1
Bþ R2⇄
k7
k8
BR2
8><
>: : (2)
Here, k1 and k3 (M
1·min1) are the association rate con-
stants of the radioligand A binding to the R1 and R2 states,
respectively, and k2 and k4 (min
1) are the dissociation rate
constants of A from the R1 and R2 states respectively. Simi-
larly, k5 (M
1·min1) and k6 (min
1) are the association and
dissociation rate constants of the competitor (B) at the R1
state, and k7 (M
1·min1) and k8 (min
1) are the association
and dissociation rate constants of B at the R2 state.
In this analysis, we assume that (i) there is no exchange
between the R1 and R2 states; (ii) only a small fraction
(<10%) of the radioligand binds to the receptor. Therefore,
the free concentration of the radioligand is approximately
constant and equal to the concentration added. Thus, the
binding reaction and the conservation of mass lead to the fol-
lowing system of ordinary differential equations (ODEs):
dAR1
dt
¼ k1AR1;tot  kA;R1AR1  k1ABR1
dAR2
dt
¼ k3AR2;tot  kA;R2AR2  k3ABR2
dBR1
dt
¼ k5BR1;tot  k5BAR1  kB;R1BR1
dBR2
dt
¼ k7BR2;tot  k7BAR2  kB;R2BR2
8>>>>><
>>>>>:
; (3)
where
kA;R1 ¼ k1Aþ k2 and kA;R2 ¼ k3Aþ k4; (4)
kB;R1 ¼ k5Bþ k6 and kB;R2 ¼ k7Bþ k8; (5)
and
R1;tot ¼ R1 þ AR1 þ BR1 and R2;tot ¼ R2 þ AR2 þ BR2: (6)
The system (Equation 3) can be viewed as a pair of two
smaller systems, one for the ligand–receptor complexes AR1
and BR1 and one for the ligand–receptor complexes AR2 and
BR2. Because there is no exchange of R1 into R2 and vice versa,
that is, R1,tot and R2,tot are constant in time, these two systems
are independent, each one of them comparable with the sys-
tem studied byMotulsky andMahan (1984). The system has a
unique steady state (AR1,ss; AR2,ss, BR1,ss, BR2,ss) where the
radioligand complexes are given by
AR1;ss ¼ k1AR1;tot k6kA;R1kB;R1  k1k5AB
AR2;ss ¼ k3AR2;tot k8kA;R2kB;R2  k3k7AB
8>><
>>:
: (7)
By assumption and experimental set-up, A and B are taken
to be constant, and therefore, the system (Equation 3) is lin-
ear and can be solved by standard methods. Each sub-system
consists of two equations, and the corresponding (2 × 2) ma-
trix of the coefficients of ARi and BRi has two eigenvalues, de-
noted by -λF,i and -λS,i where λF,i > λS,i > 0 for i = 1,2. For the
binding to R1, they are given by
λF;1 ¼ 12 kA;R1 þ kB;R1
 þ ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffikA;R1  kB;R1 2 þ 4k1k5AB
q 
λS;1 ¼ 12 kA;R1 þ kB;R1
  ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffikA;R1  kB;R1 2 þ 4k1k5AB
q 
8>><
>>:
;
(8)
and for the binding to R2, they are given by
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λF;2 ¼ 12 kA;R2 þ kB;R2
 þ ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffikA;R2  kB;R2 2 þ 4k3k7AB
q 
λS;2 ¼ 12 kA;R2 þ kB;R2
  ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffikA;R2  kB;R2 2 þ 4k3k7AB
q 
8>><
>>:
:
(9)
For the temporal behaviour of the ligand–receptor com-
plex AR1 and AR2, we then find the expressions
AR1 tð Þ ¼ AR1;ss  P1eλF;1t Q1eλS;1t
AR2 tð Þ ¼ AR2;ss  P2eλF;2t Q1eλS;2t
(
; (10)
where Pi and Qi are constants to be determined from the ini-
tial conditions. It is assumed that initially, no radioligand
and no competitor are bound to either receptor state, that is,
AR1 0ð Þ ¼ 0; AR2 0ð Þ ¼ 0; BR1 0ð Þ ¼ 0; BR2 0ð Þ ¼ 0: (11)
Using this in the expression given in Equation 10 as well
as the differential equations, we obtain for the constants Pi
and Qi:
P1 ¼ k1AR1;tot  λS;1AR1;ssλF;1  λS;1 and Q1 ¼
λF;1AR1;ss  k1AR1;tot
λF;1  λS;1
P2 ¼ k3AR2;tot  λS;2AR2;ssλF;2  λS;2 and Q2 ¼
λF;2AR2;ss  k3AR2;tot
λF;2  λS;2
8>><
>>:
:
(12)
Clearly, the solution of the system (Equation 3) can be
expressed as the sum of the solutions of two sub-systems:
ARtot tð Þ ¼ AR1 tð Þ þ AR2 tð Þ
BRtot tð Þ ¼ BR1 tð Þ þ BR2 tð Þ:
(13)
Because of difficulties with estimating the binding rate
constants for the R2 receptor, we investigate the dynamics at
the R2 state more closely. Thus, we write the equations in (3),
which involve R2 separately in greater detail so that the
parameters are all explicitly apparent:
dAR2
dt
¼ k3AR2;tot  k3Aþ k4ð ÞAR2  k3ABR2
dBR2
dt
¼ k7BR2;tot  k7BAR2  k7Bþ k8ð ÞBR2
8><
>: : (14)
Subsequently, we divide them by their respective on-rates:
the one for AR2 by k3 and the one for BR2 by k7. This yields a
system with the concentrations of AR2 and BR2 and the affin-
ities of A (KA,2) and B (KB,2) to R2 on the right:
1
k3
dAR2
dt
¼ AR2;tot  Aþ KA;2
 
AR2  ABR2
1
k7
dBR2
dt
¼ BR2;tot  BAR2  Bþ KB;2
 
BR2
8><
>: : (15)
In this manner, we have singled out the on-rates on the
left-hand sides of the two equations, and the right-hand side
is entirely composed of concentrations and affinities.
We now scale the time variable and define τ = k3·t so that
AR2 varies on a temporal scale of order unity. In addition, we
define the ratio of k3 and k7 as ε and introduce this time-
variable into the system (Equation 15) to yield
dAR2
dτ
¼ AR2;tot  Aþ KA;2
 
AR2  ABR2
εdBR2
dτ
¼ BR2;tot  BAR2  Bþ KB;2
 
BR2
8><
>: ε ¼
k3
k7
: (16)
If the ratio ε is much lower than unity, it follows from
Singular Perturbation Theory (Bender and Orszag, 1999) that
the dynamics of BR2 is much faster than that of AR2 and that
BR2 very quickly reaches a quasi-static state:
BR2 ¼ BBþ KB;2 R2;tot  AR2
 
; (17)
so that BR2 moves in lockstep with (R2,tot  AR2), and the
binding of AR2 and BR2 is quickly synchronized.
Data analysis
All experimental data were analysed using Graphpad Prism
6.0 (Graphpad Software, Inc., San Diego, CA, USA).
Association data were fitted using two phase association to
obtain the observed association rates kA;R1 and kA;R2
 
. kon
values (k1 and k3) of [
3H]-NECA were obtained from
kA;R1 and kA;R2 values using Equation 4, where k2 and k4 were
obtained from independent dissociation experiments. Disso-
ciation data were fitted and allowed the software to compare
with the extra-sum-of-square F test between the equations
Dissociation: one-phase exponential decay and biphasic exponen-
tial decay (threshold P value ≤0.01). Association and dissocia-
tion rate constants for unlabelled ligands were calculated by
fitting the data in the two-state competition association
model (entering the model into Graphpad Prism 6.0 is de-
tailed in Supporting Information). The data and statistical
analysis comply with the recommendations on experimental
design and analysis in pharmacology (Curtis et al., 2015).
Materials
[3H]-NECA (specific activity 29.4 Ci·mmol1) was purchased
from Perkin Elmer (Groningen, The Netherlands). Unlabelled
NECA and DPCPX were purchased from Sigma-Aldrich
(Steinheim, Germany), and CPA was obtained from Abcam
(Cambridge, UK). LUF5962 was synthesized in our laboratory
(Chang et al., 2006). Adenosine deaminase was purchased
from Boehringer Mannheim (Mannheim, Germany). CHAPS
was obtained from Carl Roth GmbH (Karlsruhe, Germany).
CHO cells stably expressing the human A1 receptor
(CHOhA1R) were kindly provided by Dr. K-N Klotz (Univer-
sity of Würzburg, Germany). All other chemicals were of ana-
lytical grade and obtained from standard commercial sources.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.
org, the common portal for data from the IUPHAR/BPS Guide
to PHARMACOLOGY (Harding et al., 2018), and are perma-
nently archived in the Concise Guide to PHARMACOLOGY
2017/2018 (Alexander et al., 2017a,b,c).
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Results
Quantification of the affinity of unlabelled
ligands
The binding affinity of two representative agonists (NECA
and CPA) and two antagonists (DPCPX and LUF5962) was de-
termined in competition binding assays. All compounds
tested produced concentration-dependent inhibition of spe-
cific [3H]-NECA binding (Figure 1), and their pIC50 values
are shown in Table 1. The obtained pIC50 values of the four
compounds were used to set the concentrations of the
unlabelled ligand in the two-state competition association
assay.
Kinetic characterization of the agonistic
radioligand
The binding kinetics of [3H]-NECA on the adenosine A1 re-
ceptor was obtained from kinetic radioligand binding assays.
It follows from Figure 2 that both the association and dissoci-
ation profiles of [3H]-NECA to and from the A1 receptor were
biphasic, consisting of a fast and a slow phase. The kinetics of
[3H]-NECA binding was calculated using Equation 4. The
values are detailed in Table 2.
Validation of the two-state model for kinetic
characterization of an unlabelled ligand in the
presence of an agonistic radioligand
The two-state model describes the binding of both a labelled
and an unlabelled ligand, the former having apparent dis-
tinct binding kinetics at two receptor states (R1 and R2). With
the predetermined association and dissociation rate
constants of [3H]-NECA, it was possible to measure the bind-
ing kinetics of unlabelled ligands using the two-state model
(Figure 3A). The unlabelled ligand was assayed at three differ-
ent concentrations to ensure that (i) the ligand tested
displayed competitive and reversible binding and (ii) the data
were sufficiently dense for analysing with the two-state
model. The data for unlabelled NECA are reported in Table 2.
Its on-rate and off-rate constants (k5 and k6) at the R1 state
were similar to the values (k1 and k2) of [
3H]-NECA. Likewise,
the on-rate and off-rate constants (k7 and k8) of unlabelled
NECA at the R2 state were on the same order as those for
[3H]-NECA (k3 and k4). This suggests that the model is suit-
able to determine the binding kinetics of unlabelled ligands.
Quantification of the association and
dissociation rate constants of an unlabelled
ligand
The binding kinetics of another representative A1 receptor ag-
onist (CPA) was examined subsequently. As shown in Table 3
and Figure 3B, rate constants for unlabelled CPA can be deter-
mined using the two-state model. Moreover, two representa-
tive A1 receptor antagonists, LUF5962 and DPCPX, were
characterized using the two-state model. As shown in
Figure 3C, D, the model appears to fit the data well for both
antagonists. This allowed us to determine the kinetics of the
two compounds at the R1 state (Table 3). However, k7 and k8
of these two antagonists at the R2 state were ambiguous with
very wide 95% confidence intervals. Evidently, the two-state
model has limitations in determining the kinetics of some
unlabelled ligands and, in particular, antagonists.
Data simulations
Data simulations were performed to further validate the two-
state model for kinetic characterization of the binding kinet-
ics of an unlabelled ligand and to explore the limitations of
the model for kinetic measurements.
First, we simulated the system (Equation 3) for competi-
tive binding of the radioligand [3H]-NECA in the presence
of unlabelled NECA to the receptor. Kinetic parameters of
both [3H]-NECA and NECA were obtained from experimental
measurements. It follows from Figure 4A that the simulated
data were similar to the experimental data, suggesting once
more that the model is suited to determine the binding kinet-
ics of unlabelled ligands. Furthermore, we only simulated the
system (Equation 6) for the total binding of [3H]-NECA at
steady state (ARtot = AR1,ss + AR2,ss) in the presence of NECA
or CPA at different concentrations, as the binding of [3H]-
NECA in the presence of DPCPX or LUF5962 could not be
simulated due to the ambiguous values for k7 and k8. This
then allowed us to compare the simulated results with the
Figure 1
Displacement of [3H]-NECA by increasing concentrations of CPA,
NECA, LUF5962 and DPCPX at the human adenosine A1 receptor.
Data shown are the mean ± SEM of five independent experiments,
each performed in duplicate.
Table 1
Affinities (pIC50 values) of CPA, NECA, LUF5962 and DPCPX for the human A1 receptor
Compound CPA NECA LUF5962 DPCPX
pIC50 8.10 ± 0.03 7.49 ± 0.03 7.13 ± 0.05 7.23 ± 0.05
Data are the mean ± SEM of five separate experiments each performed in duplicate.
A two-state model for kinetic investigation
British Journal of Pharmacology (2018) 175 1719–1730 1723
Figure 2
(A) The association of [3H]-NECA to the human adenosine A1 receptor. Data shown are the mean ± SEM of seven independent experiments, each
performed in duplicate (B). The dissociation of [3H]-NECA from the human adenosine A1 receptor. Data are the mean ± SEM of five independent
experiments, each performed in duplicate. Data were best fitted using a biphasic exponential decay (black solid line, comparison with the extra-
sum-of-square F test, P value <0.0501). The rejected one phase exponential decay fitting of the data is shown with the red dotted line.
Table 2
Kinetic profiles of [3H]-NECA and unlabelled NECA on the human A1 receptor
k1 (M
1·min1) k2 (min
1) KA,1 (nM) k3 (M
1·min1) k4 (min
1) KA,2 (nM)
c Fraction fast (%)c
[3H]-NECAa 1.4 ± 0.2 × 107 0.046 ± 0.007 3.2 ± 0.7 5.8 ± 0.5 × 105 0.0076 ± 0.0004 13 ± 1 32 ± 4
k5 (M
1·min1) k6 (min
1) KB,1 (nM) k7 (M
1·min1) k8 (min
1) KB,2 (nM) –
NECAb 1.4 ± 0.2 × 107 0.074 ± 0.019 5.3 ± 1.6 1.1 ± 0.6 × 106 0.019 ± 0.007 17 ± 11 –
aData were obtained from kinetic radioligand binding experiments on the A1 receptor . Data are the mean ± SEM of seven (association) and five (dis-
sociation) separate experiments, respectively, each performed in duplicate. KA,1 = k2/k1 and KA,2 = k4/k3
bData were obtained from two-state competition association assay on the A1 receptor. Data are the mean ± SEM of five separate experiments each
performed in duplicate. KB,1 = k6/k5 and KB,2 = k8/k7
cData were obtained from radioligand dissociation experiments on the A1 receptor and fitted in two-phase exponential decay. Data are themean ± SEM of
five separate experiments each performed in duplicate.
Figure 3
Two-state competition association experiment with [3H]-NECA in the absence or presence of unlabelled NECA (A), CPA (B), LUF5962 (C) and
DPCPX (D). Data shown are the mean ± SEM of five independent experiments, each performed in duplicate.
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experimental data from the competition binding assays
(Figure 1). As shown in Figure 4B, the simulated data were
in accordance with our experimental determinations, further
confirming that themodel is sufficient to determine the bind-
ing kinetics of unlabelled ligands. In addition, we performed
data simulations using different k8 values while maintaining
other parameters identical (Figure 5). We found that a slow
dissociation from one receptor state can induce an ‘over-
shoot’ (as in the blue and green curves), and the pattern be-
comes more significant with a significantly smaller k8 value.
As shown in Figure 5, a compound with a k8 value of 2.1 x
10-4 min1 displayed a clear overshoot while the compound
with a 100-fold larger k8 value (2.1 x 10
-2 min) did not.
Investigating the limitations of the current
radioligand in determining the binding kinetics
with the two-state model
The two-state model can reproduce and quantify the
binding kinetics of NECA and CPA, as demonstrated by
both experimental and simulation results. However, k7
and k8 values for DPCPX and LUF5962 could not be ac-
curately determined in the two-state model by using
[3H]-NECA, which displayed relatively slow kinetics at both
R1 (k1 = 1.4 ± 0.2 × 10
7 M1·min1, k2 = 0.046 ± 0.007 min
1)
and R2 states (k3 = 5.8 ± 0.5 × 10
5 M1·min1 and
k4 = 0.0076 ± 0.0004 min
1). Additional data analysis was
therefore performed to understand the limitations of using
Table 3
Kinetic profiles of an unlabelled agonist, CPA and two unlabelled antagonists, DPCPX and LUF5962, on the human A1 receptor using the two-state
model
k5 (M
1·min1) k6 (min
1) KB,1 (nM) k7 (M
1·min1) k8 (min
1) KB,2 (nM)
CPA 5.2 ± 0.1 × 107 0.025 ± 0.011 0.48 ± 0.21 1.8 ± 0.4 × 106 0.0095 ± 0.0032 5.2 ± 2.1
DPCPX 2.1 ± 1.4 × 108 0.78 ± 1.42 3.7 ± 7.1 6.2 × 1013a 3.4 × 106a 55a
LUF5962 1.0 ± 0.4 × 107 0.23 ± 0.10 23 ± 66 2.3 × 1014a 3.4 × 106a 15a
Data are the mean ± SEM of five separate experiments each performed in duplicate. Data were obtained from two-state competition association assay
on the A1R.
aMean values obtained by using the two-state model. Data were ambiguous with very wide 95% confidence intervals.
Figure 4
(A) Comparison of the simulated kinetic radioligand binding (lines)
with the experimental data (circles) of [3H]-NECA in the presence
of unlabelled NECA at different concentrations (0 nM; 10 nM;
30 nM and100 nM). Data are shown as normalized values to the to-
tal binding of the radioligand at both R1 and R2 states. (B) Compari-
son of the simulated radioligand binding (lines) at the steady state
with the experimental data from [3H]-NECA displacement experi-
ments in the presence of a competitor at different concentrations
(1 × 1010 M to 1 × 105 M; circles). The kinetic parameters of
[3H]-NECA and the competitors (NECA and CPA) for data simulations
were obtained from Tables 2 and 3. Data are shown as normalized
values to the total binding of the radioligand at both R1 and R2 states.
Figure 5
Data simulations of [3H]-NECA in the presence of ligands with differ-
ent k8 values (2.1 × 10
2 min1; 2.1 × 103min1 ; 2.1 × 104 min1)
while k5 (1.4 × 10
7 M1·min1), k6 (0.074 min
1) and k7
(1.1 × 106 M1·min1) were kept constant. The kinetic parameters
of [3H]-NECA for data simulations were obtained from Table 2. Data
are shown as normalized values to the total binding of the
radioligand at both R1 and R2 states.
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the current radioligand. Given that the kinetics for both com-
pounds was ambiguous at the R2 state, we specifically focused
on the binding of the radioligand and the competitor in the
system (Equation 14). Upon simulating the binding of BR2
with different ε values (ε = k3/k7, Figure 6), we observed that
the time for BR2 to reach the quasi-static state (Equation 17)
was indeed shorter after changing the k7 values, while keep-
ing the KB;R2 fixed at 55 nM. Notably, when ε was small
(Figure 6A, ε = 1.5 × 108; and Figure 6B, ε = 1.5 × 103), BR2
reached the quasi-static state in much less than 1 min, which
was, in fact, our first experimental assay point. This implies
that the transient binding of A and B at the R2 state cannot
be sufficiently recorded experimentally before the quasi-static
state has been reached. As a result, kinetic characterization of
an unlabelled ligand at the R2 state becomes unreliable, which
is probably the case for the antagonists DPCPX and LUF5962.
Indeed, the association rates of DPCPX and LUF5962 were
2.0 × 108 M1·min1 and 1.2 × 108 M1·min1, respectively,
determined previously at 25°C (Guo et al., 2013), and it is
therefore reasonable to speculate that the values will be even
higher at 30°C, hence resulting in ε values lower than 0.001.
In contrast, when ε was increased to 0.15 or 1.5, the binding
of BR2 required a longer incubation period (i.e. more than
3 min) to reach the quasi-static state (Figure 6C, D). Notably,
the ε values for NECA and CPA were determined as 0.52 (k3/
k7 = 5.8 × 10
5/1.1 × 106, data from Table 2) and 0.32 (k3/
k7 = 5.8 × 10
5/1.8 × 106, data from Tables 2 and 3), respec-
tively, that is, significantly higher than the ε values of DPCPX
and LUF5962, hence resulting in reliable kinetic
measurements.
Furthermore, we compared the simulated competitive as-
sociation of the radioligand [3H]-NECA to the receptor in the
presence of unlabelled DPCPX with the experimental data
(Figure 7). It follows from Figure 7A that the simulated data
were similar to the experimental data. Next, we reduced
the k7 value of DPCPX to 6.2 × 10
8 M1·min1 (Figure 7B),
6.2 × 106 M1·min1 (Figure 7C) and 6.2 × 105 M1·min1
(Figure 7D). This yielded corresponding ε values of
1.5 × 103, 0.15 and 1.5. Simultaneously, the k8 values were
reduced to 3.4 min1, 0.034 min1 and 0.0034 min1, re-
spectively, so that KB,2 was kept fixed at 55 nM. Interestingly,
the simulated curves in Figure 7B, C for the reduced rate con-
stants fit the experimental data just as well as those in
Figure 7A. In contrast, when further increasing the ε value
to 1.5 (Figure 7D), the simulated curves significantly devi-
ated from the experimental data. Together, these results
Figure 6
Data simulations of the binding of DPCPX (200 nM) at the R2 state (BR2) and its binding at the quasi-static state. The off-rates of [
3H]-NECA
from the R1 and R2 states for simulations were from radioligand dissociation experiments (k2 = 0.046 min
1 and k4 = 0.0076 min
1), while
the on-rates of [3H]-NECA to the R1 and R2 states for simulation were obtained by analysing the kinetic binding of [
3H]-NECA in the absence
of the competitor in the two-state competition association assays (k1 = 1.4 × 10
7 M1·min1, k3 = 1.1 × 10
6 M1·min1). The k5 and k6 values of
unlabelled DPCPX for simulation were 2.1 × 108M1·min1 and 0.775min1 respectively. The k7 and k8 values of unlabelled DPCPX for simulation
were (A) 6.2 × 1013 M1·min1 and 3.4 × 105 min1, (B) 6.2 × 108 M1·min1 and 3.4 min1, (C) 6.2 × 106 M1·min1 and 0.034 min1 or (D)
6.2 × 105 M1·min1 and 0.0034 min1.
D Guo et al.
1726 British Journal of Pharmacology (2018) 175 1719–1730
imply that the kinetics of DPCPX at the R2 state was very fast
with a low ε value (at least less than 1.5). In our current
work, the actual magnitude of k7 and k8 of an antagonist
has little effect on the graph of AR2 (t), reflecting the
ambiguous k7 and k8 values for DPCPX determined by the
two-state model.
Discussion
TheMotulsky andMahanmodel makes it possible to measure
the binding kinetics of an unlabelled ligand, which provides
the practical convenience of not needing to label every ligand
of interest (Motulsky and Mahan, 1984). However, the appli-
cation of the model is limited because of the assumption that
the labelled reference ligand does not have preference for any
particular receptor state, hence representing a one-state
model. A labelled probe, for example, a radioligand, may dis-
play biphasic kinetic binding, representing different binding
kinetics to different receptor states (Munshi et al., 1985; van
Veldhoven et al., 2015). A number of reasons may be relevant
to the nature of the biphasic kinetic binding. For a GPCR as
an example, there may be an active state bound to a G protein
and an inactive state that is not bound to a G protein. It is also
possible that the kinetic difference is due to the ligand
interacting with receptors that exist in various structures of
membrane preparations. For instance, a portion of the recep-
tors may be present in vesicular structures, and are thus less
accessible (Cohen et al., 1996). Similarly, for other drug tar-
gets, different states or conformationsmay exist, for instance,
an ion channel has open and closed states (Hill et al., 2014).
Whatever the reason, under these circumstances the kinetics
of unlabelled ligand binding cannot be characterized. Thus, it
is important to develop a new mathematical model for a two-
state system, yielding a quantitative assessment of the kinetic
parameters of both probe and unlabelled competitor. In the
present study, we have developed and validated such a two-
state model for kinetic characterization. This method may
well fill a niche and become of practical value, especially for
targets for which a radiolabeled antagonist is not available,
such as theHCA receptors (Offermanns et al., 2011), or tar-
gets where the radiolabeled antagonist is not ideal for accu-
rate kinetic measurements due to high non-specific binding.
An important variable to optimize in the two-state model
for accurate kinetic determinations was the concentration of
the unlabelled ligand as in the one-state model (Dowling and
Charlton, 2006). Firstly, it appeared necessary to use at least
three concentrations to ensure reliable calculations. Reduc-
ing assay points with fewer concentrations tends to compro-
mise the quality of the data analysis with lower reliability or
even ambiguity, as reflected by wider 95% confidence inter-
vals. Secondly, we found that lower competitor concentra-
tions will have little influence on the radioligand
association process, leading to a high degree of error in rate
estimates for the unlabelled ligand. In contrast, a higher con-
centration of the competing ligand might cause little
Figure 7
Comparison of the simulated kinetic radioligand binding (lines) with the experimental data (circles) of [3H]-NECA in the presence of
unlabelled DPCPX at different concentrations (0 nM; 20 nM; 60 nM and 200 nM). Data are shown as normalized values to the total binding
of the radioligand at both R1 and R2 states. The off-rates of [
3H]-NECA from the R1 and R2 states for simulation were from radioligand
dissociation experiments (k2 = 0.046 min
1 and k4 = 0.0076 min
1), while the on-rates of [3H]-NECA to the R1 and R2 states for simulation
were obtained by analysing the kinetic binding of [3H]-NECA in the absence of the competitor in the two-state competition association assays
(k1 = 1.4 × 10
7 M1·min1, k3 = 1.1 × 10
6 M1·min1). The k5 and k6 values of unlabelled DPCPX for simulation were 2.1 × 10
8 M1·min1
and 0.775 min1 respectively. The k7 and k8 values of unlabelled DPCPX for simulation were (A) 6.2 × 10
13 M1·min1 and 3.4 × 105 min1,
(B) 6.2 × 108 M1·min1 and 3.4 min1, (C) 6.2 × 106 M1·min1 and 0.034 min1 or (D) 6.2 × 105 M1·min1 and 0.0034 min1.
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radioligand binding remaining, also preventing ameaningful
data analysis. Thus, we used 0.3-fold, 1-fold and 3-fold of the
IC50 value of the relevant compound, obtained from displace-
ment experiments to generate reproducible and accurate rate
constants.
We also found other assay conditions that are critical for
accurate kinetic determinations. It is essential to include
sufficient time points for the binding of the radioligand in
the absence or presence of an unlabelled competitor, partic-
ularly in the fast associating phase and the intersection of
both fast and slow phases (e.g. Figure 2, before 30 min), to
better capture the biphasic association pattern of the
agonistic radioligand. Another critical factor to optimize is
the assay temperature. Increasing the assay temperature en-
hances the rates of association to both states. As a result, it
might shift the biphasic radioligand association into a
pseudo-one phasic process (which might also happen when
one has sparse time points), hence affecting the accuracy of
the assay. In the present study, we performed the assay at
30°C. At this temperature, the kinetics of [3H]-NECA at
the R1 state were 1.4 ± 0.2 × 10
7 M1·min1 (association)
and 0.046 ± 0.007 min1 (dissociation). Thus, its observed
association rate (kA;R1 ) can be calculated as 0.298 min
1
( kA;R1 = k1 × A + k2, A = 18 nM). Similarly, its observed
association rate (kA;R2 ) to the R2 state can be calculated as
0.0178min1 (kA;R2 = k3 × A + k4, k3 = 5.8 ± 0.5 × 10
5M1·min1,
k4 = 0.0076 ± 0.0004 min
1, A = 18 nM). Their respective
half-lives are 2.33 min and 38.9 min ( t1=2;R1 ¼ ln2=kA;R1 ;
t1=2;R2 ¼ ln2=kA;R2), different by a factor of 17. Evidently, this
difference is sufficient to generate the biphasic association
curve of the radioligand. Furthermore, a critical condition for
the successful application of the two-state model was found
to be that the on-rate to each receptor, that is, k1 and k5
(R1) as well as k3 and k7 (R2) are of similar order of magnitude.
This ensures that the resulting graphs are truly biphasic and
clearly exhibit the different convergence rates involved.
According to the theory for a one-state model developed
by Motulsky and Mahan, initial radioligand binding over-
shoots its equilibrium occupancy when the dissociation of
the competitor is slower than that of the radioligand. An ex-
ample was provided in our previous research, in which an
A2A receptor agonist,UK432,097, displayed a slower disso-
ciation rate constant (koff = 0.004 min
1) than the
radioligand (koff = 0.01 min
1), resulting in an initial over-
shoot of radioligand binding (Guo et al., 2012). The theoreti-
cal basis of this overshoot also allows one to modify the full
competition association assay into a high-throughput for-
mat, enabling fast kinetic screening (Guo et al., 2013). In
comparison, the two-state system contains two sets of
‘micro-kinetics’, which increases the difficulty of qualita-
tively judging the occurrence of overshoot. An overshoot will
occur if k6 < k2 and k8< k4; and an overshoot will not occur if
k6 > k2 and k8 > k4. In cases where k6 < k2 and k8 > k4 or
k6 > k2 and k8 < k4, the overshoot may or may not occur, de-
pending on the relative ratio of the R1 and R2 populations, as
well as the values of the rate constants k6 and k8. In the pres-
ent study, CPA displayed faster dissociation rate constants
compared with the radioligand, and no overshoot was
observed indeed. We also performed data simulations using
different k8 values while maintaining other parameters iden-
tical. It follows from Figure 5 that a slow dissociation from
one receptor state can induce the overshoot, and the pattern
becomesmore significantwith a significantly smaller k8 value
(i.e. k8 = 0.0021 min
1) while not so for the case where k8 is
10-fold faster. Thus, one needs to be cautious in using the
overshoot phenomenon for kinetic screening in the context
of a two-state model.
The two-state model enables us to separate the binding
kinetics to two receptor states. However, one needs to con-
sider several limitations while applying the model for ki-
netic measurements. Firstly, one cannot attribute the
values at the R1 and R2 states to a specific conformation or
state of the receptor. For GPCRs, it is likely that the fast
association/dissociation phase is related to the G protein-
uncoupled state/the inactive state, while the slow
association/dissociation phase is correlated to the G
protein-coupled state/the active state (Casarosa et al., 2011;
Cohen et al., 1996). Secondly, it is also important to point
out that the kinetic characterization was performed using
membrane preparations, where we assume both R1 and R2
populations are unable to significantly convert into each
other, at least during the time frame of the measurements.
However, under other conditions, such as in whole-cell
based experiments, both populations are not necessarily
fixed (Kenakin, 2001), and their respective magnitude is able
to vary in the often-evoked induced-fit model (Vauquelin
et al., 2016), not only for agonists (De Lean et al., 1980) but
also for antagonists (Vauquelin et al., 2001). In these circum-
stances, one should be cautious in using the two-state model
for kinetic determinations. Instead, numerical simulations
might be needed for such more complex situations
(Woodroffe et al., 2009; Bridge et al., 2010). Thirdly, if the
radioligand has relatively slow association kinetics, it might
yield limitations in measuring unlabelled ligands with faster
kinetics, as seems to be the case for DPCPX and LUF5962.
One could consider using another radioligand with faster as-
sociation kinetics, if available, to increase the ratio of k3 and
k7. Additionally, the method remains laborious as it requires
a sufficiently high number of data points for reliable kinetic
estimation. To further adapt the assay into a high-
throughput format, one may consider combining the two-
state model with homogenous binding assay techniques,
such as the scintillation proximity assay (Xia et al., 2016) or
the time-resolved fluorescence energy transfer assay (Schiele
et al., 2015; Nederpelt et al., 2016), which allow continuous
readout of ligand–receptor binding without physical separa-
tion between free and bound ligands.
To conclude, we have introduced a two-state model
containing two receptor states, R1 and R2, for kinetic profil-
ing of an unlabelled competitor using an agonist
radioligand. The new model comprises a linear system of
ODEs for which we can find analytical solutions. This
makes further analysis feasible and is straightforward to
simulate with (no need for numerical differential equation
solvers). We believe that with the correct technical applica-
tion of the two-state model, one can determine the kinetics
of unlabelled ligands using an agonist radioligand, as
shown for ligands at the human adenosine A1 receptor, as
a prototypical GPCR. The two-state model may have
general applicability on other drug targets as well, thereby
enabling more kinetics-directed research in the early phases
of the drug discovery process.
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